<![CDATA[Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL ]]>

CAR T-Cell Therapies and Tirabrutinib in PCNSL: HighlightsAs CAR T-cell therapy is integrated into the PCNSL treatment paradigm, one key aspect is the management of neurologic AEs in patients with a malignancy primarily affecting the CNS.Tirabrutinib represents an oral, well-tolerated potential treatment option for patients with relapsed/refractory PCNSL.The FDA is currently reviewing a new drug application for tirabrutinib in relapsed/refractory PCNSL, and the agent is being further evaluated in the ongoing phase 3 IGNITE trial.